ReviewCurrent opinion in genetics & development2018
Insights from structures of cancer-relevant pre-mRNA splicing factors.
Review in Current opinion in genetics & development, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- The effect of U2AF1 mutation on erythroid differentiation and sensitivity to demethylation drug treatment.Medical oncology (Northwood, London, England) · 2025Article
- A common structural mechanism for RNA recognition by the SF3B complex in mRNA splicing and export.Nucleic acids research · 2025Article
- U2AF1 in various neoplastic diseases and relevant targeted therapies for malignant cancers with complex mutations (Review).Oncology reports · 2024Review
- CRISPR-assisted transcription activation by phase-separation proteins.Protein & cell · 2023Article
- Therapeutic Targeting of RNA Splicing in Cancer.Genes · 2023Review
- Pre-mRNA splicing factor U2AF2 recognizes distinct conformations of nucleotide variants at the center of the pre-mRNA splice site signal.Nucleic acids research · 2022Article
- The SF3b complex: splicing and beyond.Cellular and molecular life sciences : CMLS · 2020Review
- Regulating Divergent Transcriptomes through mRNA Splicing and Its Modulation Using Various Small Compounds.International journal of molecular sciences · 2020Review
- Targeting mRNA processing as an anticancer strategy.Nature reviews. Drug discovery · 2020Review
- Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies.Genes, chromosomes & cancer · 2019Review
- The splicing factor U2AF1 contributes to cancer progression through a noncanonical role in translation regulation.Genes & development · 2019Article
- U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions.Leukemia · 2018Article
- Functional analysis of Hsh155/SF3b1 interactions with the U2 snRNA/branch site duplex.RNA (New York, N.Y.) · 2018Article
- SRSF2 mutations in myelodysplasia/myeloproliferative neoplasms.Biomarker research · 2018Review
- Blood Relatives: Splicing Mechanisms underlying Erythropoiesis in Health and Disease.F1000Research · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Pre-mRNA splicing factors recognize consensus signals within preliminary transcripts, and as cogs of the spliceosome machine, orchestrate the excision and rejoining of pre-mRNA regions for gene expression. Large-scale sequencing has demonstrated that mutations in key genes encoding pre-mRNA splicing factors are common among myeloid neoplasms and also occur in a variety of other cancers. This revelation offers new therapeutic opportunities to target pre-mRNA splicing vulnerabilities in hematologic and other malignancies. The mutated residues typically alter 3' splice site choice for a subset of transcripts. In this review, we highlight mechanistic insights from recent 3D structures that reveal the affected residues poised for pre-mRNA recognition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.